Chong Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chong Feng has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Cheng Zhang
The First Affiliated Hospital of Anhui Medical University
3 shared publications - Hui Xu
Department of Oncology The First Affiliated Hospital of Anhui Medical University Hefei People's Republic of China
3 shared publications - Minmin Xie
Department of Oncology The First Affiliated Hospital of Anhui Medical University Hefei People's Republic of China
3 shared publications - Tai Ma
Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of China
3 shared publications - Xiaopeng Zhang
Department of Noncommunicable Diseases and Health Education Hefei Center for Disease Control and Prevention Hefei People's Republic of China
3 shared publications - Yahui Yang
Department of Oncology The First Affiliated Hospital of Anhui Medical University Hefei People's Republic of China
3 shared publications
Latest Publications
- Open Access
- 4 September 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (3) , 2831-2841
Incorporation of liver chemistry score in predicting survival of liver‐involved advanced gastric cancer patients who received palliative chemotherapy
Background: Gastric cancer liver metastasis (GCLM) patients usually accompany by abnormal serum liver function tests (LFTs) more or less; however, the prognostic value of LFTs is not fully understood. This study aimed to develop a liver chemistry score (LCS) based on LFTs and incorporate it into prognosis determination for GCLM patients who received palliative chemotherapy.Methods: Data were derived from hospitalized GCLM patients in two general hospitals in China. LCS was generated based on the results of LFTs by LASSO regression. Cutoff value of the score was determined by restricted cubic spline. The score was then incorporated into Cox regression analysis to construct a predictive nomogram; the model was then evaluated internally and externally by AUC of time‐dependent receiver operating characteristic curves (ROC) and calibration curves.Results: Three hundred and thirty‐six and 72 patients were included in development and validation cohort, respectively. LASSO regression analysis in development cohort finally reached a two‐parametric LCS calculated on AST and ALP levels as 0.03343515 × ln (AST, U/L) + 0.02687997 × ln (ALP, U/L), and 0.232 was set as optimal cutoff value. Patients in low (LCS < 0.232) or high (LCS ≥ 0.232) score group experienced different survival times; median OS was 13.54 (95% CI: 11.1–15.6) months in the low LCS group and 7.3 (6.6–9.3) months in the high LCS group (p < 0.001). A nomogram including LCS and other clinical parameters was constructed and showed superior performance than model not including LCS. AUC of 6‐month ROC improved from 0.647 (95% CI: 0.584–0.711) to 0.699 (0.638–0.759) in internal validation, and 0.837 (0.734–0.940) to 0.875 (0.784–0.966) in external validation.Conclusions: Liver chemistry score is useful in determining the prognosis of gastric cancer patients with liver metastasis and may be helpful to clinicians in decision‐making.
- 4 September 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (3) , 2831-2841
Open AccessIncorporation of liver chemistry score in predicting survival of liver‐involved advanced gastric cancer patients who received palliative chemotherapy
Background: Gastric cancer liver metastasis (GCLM) patients usually accompany by abnormal serum liver function tests (LFTs) more or less; however, the prognostic value of LFTs is not fully understood. This study aimed to develop a liver chemistry score (LCS) based on LFTs and incorporate it into prognosis determination for GCLM patients who received palliative chemotherapy.Methods: Data were derived from hospitalized GCLM patients in two general hospitals in China. LCS was generated based on the results of LFTs by LASSO regression. Cutoff value of the score was determined by restricted cubic spline. The score was then incorporated into Cox regression analysis to construct a predictive nomogram; the model was then evaluated internally and externally by AUC of time‐dependent receiver operating characteristic curves (ROC) and calibration curves.Results: Three hundred and thirty‐six and 72 patients were included in development and validation cohort, respectively. LASSO regression analysis in development cohort finally reached a two‐parametric LCS calculated on AST and ALP levels as 0.03343515 × ln (AST, U/L) + 0.02687997 × ln (ALP, U/L), and 0.232 was set as optimal cutoff value. Patients in low (LCS < 0.232) or high (LCS ≥ 0.232) score group experienced different survival times; median OS was 13.54 (95% CI: 11.1–15.6) months in the low LCS group and 7.3 (6.6–9.3) months in the high LCS group (p < 0.001). A nomogram including LCS and other clinical parameters was constructed and showed superior performance than model not including LCS. AUC of 6‐month ROC improved from 0.647 (95% CI: 0.584–0.711) to 0.699 (0.638–0.759) in internal validation, and 0.837 (0.734–0.940) to 0.875 (0.784–0.966) in external validation.Conclusions: Liver chemistry score is useful in determining the prognosis of gastric cancer patients with liver metastasis and may be helpful to clinicians in decision‐making.
- Open Access
- 1 January 2022
- Published by XMLink in Journal of Gastric Cancer
- Vol. 22 (2) , 120-134
Determination of Survival of Gastric Cancer Patients With Distant Lymph Node Metastasis Using Prealbumin Level and Prothrombin Time: Contour Plots Based on Random Survival Forest Algorithm on High-Dimensionality Clinical and Laboratory Datasets
Zhang C, et al. J Gastric Cancer. 2022 Apr;22(2):120-134. https://doi.org/10.5230/jgc.2022.22.e12
- 1 January 2022
- Published by XMLink in Journal of Gastric Cancer
- Vol. 22 (2) , 120-134
Open AccessDetermination of Survival of Gastric Cancer Patients With Distant Lymph Node Metastasis Using Prealbumin Level and Prothrombin Time: Contour Plots Based on Random Survival Forest Algorithm on High-Dimensionality Clinical and Laboratory Datasets
Zhang C, et al. J Gastric Cancer. 2022 Apr;22(2):120-134. https://doi.org/10.5230/jgc.2022.22.e12
- Open Access
- 1 January 2021
- Published by The Korean Gastric Cancer Association in Journal of Gastric Cancer
- Vol. 21 (3) , 268-278
Performances of Prognostic Models in Stratifying Patients with Advanced Gastric Cancer Receiving First-line Chemotherapy: a Validation Study in a Chinese Cohort
Xu H, et al. J Gastric Cancer. 2021 Sep;21:e26. https://doi.org/10.5230/jgc.2021.21.e26
- 1 January 2021
- Published by The Korean Gastric Cancer Association in Journal of Gastric Cancer
- Vol. 21 (3) , 268-278
Open AccessPerformances of Prognostic Models in Stratifying Patients with Advanced Gastric Cancer Receiving First-line Chemotherapy: a Validation Study in a Chinese Cohort
Xu H, et al. J Gastric Cancer. 2021 Sep;21:e26. https://doi.org/10.5230/jgc.2021.21.e26
- Retracted
- 7 November 2017
- Published by Taylor & Francis in International Journal of Psychiatry in Clinical Practice
- Vol. 23 (4) , 245-250
Retracted Article: Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study
We, the Editors and Publishers of the International Journal of Psychiatry in Clinical Practice, have retracted the following article: Jing Wang, Xi-Fang Liu, Chong Feng, Quan Bao & Hong-Ran Fu (2017) Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study, International Journal of Psychiatry in Clinical Practice, 23:4, 245-250, DOI: 10.1080/13651501.2017.1397700 After publication, concern was raised over the use of Vortioxetine which was not licensed for use in China at the time of the study. We have tried repeatedly to get clarification from the authors regarding the data, approval for use of the Vortioxetine and the supplier of Vortioxetine but have had no replies. We have informed the authors that their article is to be retracted due to these integrity issues. We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions. The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.
- 7 November 2017
- Published by Taylor & Francis in International Journal of Psychiatry in Clinical Practice
- Vol. 23 (4) , 245-250
RetractedRetracted Article: Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study
We, the Editors and Publishers of the International Journal of Psychiatry in Clinical Practice, have retracted the following article: Jing Wang, Xi-Fang Liu, Chong Feng, Quan Bao & Hong-Ran Fu (2017) Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study, International Journal of Psychiatry in Clinical Practice, 23:4, 245-250, DOI: 10.1080/13651501.2017.1397700 After publication, concern was raised over the use of Vortioxetine which was not licensed for use in China at the time of the study. We have tried repeatedly to get clarification from the authors regarding the data, approval for use of the Vortioxetine and the supplier of Vortioxetine but have had no replies. We have informed the authors that their article is to be retracted due to these integrity issues. We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions. The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.